arrow
X

Xavier Leleu

hospital of poitiers
H指数:93
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

DREAMM-3研究的最终分析结果:belantamab mafodotin与pomalidomide联合dexamethasone治疗复发/难治性多发性骨髓瘤的III期研究

2026-10-170
OAAI
Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

皮下注射isasutuximab(通过自体注射器)联合硼替佐米、来那度胺和地塞米松治疗新诊断的移植不合格多发性骨髓瘤:ISASOCUT研究

2026-10-090
OAAI
MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study

MK-4002,一种靶向B细胞成熟抗原的T细胞接合剂,在复发或难治性多发性骨髓瘤中的应用:一项首次人体、开放标签的1期研究

2026-10-060
PRE
Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05)

BENEFIT研究(IFM2020-05)中高危初诊非移植候选多发性骨髓瘤的MRD纵向评估

2026-10-050
OAAI
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

达拉妥木单抗、来那度胺和地塞米松在移植不适宜的新诊断多发性骨髓瘤中的应用:MAIA最终生存分析

Leukemia
IF13.4
2026-08-240
OA
Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study

新诊断多发性骨髓瘤患者SLIM标准下的临床结局:CASSIOPEIA研究中的亚组分析

Leukemia
IF13.4
2026-08-130
PRE
Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

Cyclin D1过表达多发性骨髓瘤的反应特征和长期结局:来自CASSIOPEIA试验的见解

2026-07-030
OAAI
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE

达拉妥单抗治疗新诊断多发性骨髓瘤患者的感染:MAIA和ALCYONE研究的合并分析

2026-05-070
OAAI
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA Trial

FDG-PET骨髓总肿瘤体积在CASSIOPEIA试验中凸显高风险新诊断多发性骨髓瘤患者

2026-03-310
OAAI
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: Dynamics of MRD-negativity in the IMROZ study

Isatuximab,bortezomib,lenalidomide,dexamethasone用于多发性骨髓瘤:IMROZ研究中MRD阴性的动态变化

Blood
IF23.1
2026-03-030
OA
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Cilta-cel 在来那度胺难治性多发性骨髓瘤中的疗效(CARTITUDE-4):一项开放标签、多中心、随机、III期试验的更新分析,包括总生存期数据

2026-01-070
OAAI
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

35年专注于高剂量疗法和自体干细胞移植的学术研究:法国骨髓瘤研究组(IFM)的经验

2025-10-240
OA
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study

减瘤策略在髓外和/或高肿瘤负荷RRMM患者接受抗BCMA/CD3双特异性抗体治疗前:一项回顾性队列研究

2025-10-210
OA
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

脆弱及新诊断多发性骨髓瘤患者中地塞米松减量方案联合达拉珠单抗和来那度胺的安全性与有效性(IFM2017-03):一项III期、开放标签、多中心、随机对照试验

2025-09-290
OAAI
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

CASSIOPEIA试验中,新诊断多发性骨髓瘤患者维持治疗前的FDG PET/CT反应的预后价值

Blood
IF23.1
2025-09-260
PRE
High-risk genomic consensus validation in newly diagnosed multiple myeloma patients using next-generation sequencing

使用下一代测序对 newly diagnosed multiple myeloma 患者进行高风险基因组共识验证

Blood
IF23.1
2025-09-260
PRE
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study

从ide-cel早期复发后使用靶向BCMA的双特异性抗体治疗效果不佳:一项法国真实世界研究

2025-09-200
OAAI